Telman Deborah H

SEC source: 0001127602-24-021048 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,631

SEC source: 0001127602-24-018411 · form4.xml · derivative · entry 3

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,930

Underlying: Common Stock · 638 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-018411 · form4.xml · nonDerivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,548

SEC source: 0001127602-24-018411 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,752

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001323885-24-000080 · wk-form4_1715720687.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,783

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001127602-24-013462 · form4.xml · derivative · entry 3

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,568

Underlying: Common Stock · 515 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-013462 · form4.xml · nonDerivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,114

SEC source: 0001127602-24-013462 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-24-009742 · form4.xml · derivative · entry 5

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,083

Underlying: Common Stock · 10,815 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009742 · form4.xml · derivative · entry 4

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,980

Underlying: Common Stock · 54,980 shares

Expires 2034-03-10

F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009742 · form4.xml · derivative · entry 3

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,268

Underlying: Common Stock · 2,555 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009742 · form4.xml · nonDerivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,757

SEC source: 0001127602-24-009742 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,603

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · balance_after: Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.

SEC source: 0001127602-24-003028 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,728

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting person on March 10, 2023. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of the performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting person until the requisite continuing service requirements are met.

SEC source: 0001127602-24-002300 · form4.xml · derivative · entry 3

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,823

Underlying: Common Stock · 514 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-002300 · form4.xml · nonDerivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,082

SEC source: 0001127602-24-002300 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,276

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-026281 · form4.xml · derivative · entry 3

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,337

Underlying: Common Stock · 514 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-026281 · form4.xml · nonDerivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,762

SEC source: 0001127602-23-026281 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,005

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-021338 · form4.xml · derivative · entry 5

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,851

Underlying: Common Stock · 2,058 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-021338 · form4.xml · derivative · entry 4

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,909

Underlying: Common Stock · 8,231 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-23-021338 · form4.xml · nonDerivative · entry 3

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-021338 · form4.xml · nonDerivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,433

SEC source: 0001127602-23-021338 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,607

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001323885-23-000061 · wk-form4_1685132316.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,995

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001127602-23-009978 · form4.xml · derivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,605

Underlying: Common Stock · 46,605 shares

Expires 2033-03-10

F3 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009978 · form4.xml · derivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,140

Underlying: Common Stock · 10,220 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-006757 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376

F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2022 through February 15, 2023. The transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 16, 2022.

SEC source: 0001323885-22-000073 · wf-form4_165365658158055.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,809

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001104659-22-056633 · tm2214603-9_4seq1.xml · derivative · entry 3

Telman Deborah H · CIK 0001860008 · EVP GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,431

Underlying: Common Stock · 4,431 shares

Expires 2024-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU.

F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations.

F3 · derivative.exercise_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024.

F3 · derivative.expiration_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024.

SEC source: 0001104659-22-056633 · tm2214603-9_4seq1.xml · nonDerivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,688

SEC source: 0001104659-22-056633 · tm2214603-9_4seq1.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,987

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU.

SEC source: 0001104659-22-042366 · tm2211465-10_4seq1.xml · derivative · entry 2

Telman Deborah H · CIK 0001860008 · Gen Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,682

Underlying: Common Stock · 39,682 shares

Expires 2032-03-29

F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025.

SEC source: 0001104659-22-042366 · tm2211465-10_4seq1.xml · derivative · entry 1

Telman Deborah H · CIK 0001860008 · Gen Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,882

Underlying: Common Stock · 12,882 shares

Expires 2025-03-31

F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU.

F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025.

SEC source: 0000899243-21-033661 · doc4.xml · derivative · entry 1

Telman Deborah H · CIK 0001860008 · Gen Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,321

Underlying: Common Stock · 22,321 shares

Expires 2031-08-16

F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024.

SEC source: 0000899243-21-032181 · doc4.xml · derivative · entry 3

Telman Deborah H · CIK 0001860008 · EVP GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,892

Underlying: Common Stock · 6,445 shares

Expires 2023-08-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023.

SEC source: 0000899243-21-032181 · doc4.xml · nonDerivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,556

SEC source: 0000899243-21-032181 · doc4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,445

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-041246 · doc4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,245

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest 33% annually over three years from date of grant.

SEC source: 0000899243-21-022184 · doc4.xml · derivative · entry 4

Telman Deborah H · CIK 0001860008 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,095

Underlying: Common Stock · 103,095 shares

Expires 2031-05-03

F7 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F8 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022184 · doc4.xml · derivative · entry 3

Telman Deborah H · CIK 0001860008 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,624

Underlying: Common Stock · 17,624 shares

Expires 2023-12-31

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F5 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F6 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022184 · doc4.xml · derivative · entry 2

Telman Deborah H · CIK 0001860008 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,296

Underlying: Common Stock · 13,296 shares

Expires 2024-05-04

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022184 · doc4.xml · derivative · entry 1

Telman Deborah H · CIK 0001860008 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,337

Underlying: Common Stock · 19,337 shares

Expires 2023-08-05

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023.